Compare UXIN & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UXIN | VSTM |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.0M | 470.7M |
| IPO Year | 2018 | 2011 |
| Metric | UXIN | VSTM |
|---|---|---|
| Price | $1.77 | $4.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 163.4K | ★ 2.3M |
| Earning Date | 04-10-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | $245.77 | $282.64 |
| Revenue Next Year | $44.72 | $72.25 |
| P/E Ratio | $4.05 | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $1.71 | $3.55 |
| 52 Week High | $5.32 | $11.25 |
| Indicator | UXIN | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 30.27 | 46.04 |
| Support Level | N/A | $4.00 |
| Resistance Level | $3.18 | $4.53 |
| Average True Range (ATR) | 0.17 | 0.29 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 5.63 | 65.71 |
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates a car retailer, pioneering industry transformation with production, new retail experiences, and digital empowerment in China. With its inventory-owning model, it provides customers a comprehensive transaction solution that encompasses the entire value chain, ranging from used-car acquisition, inspection, and reconditioning, warehousing, as well as pre-sales and after-sales services. The group offers high-quality and value-for-money used cars as well as superior full suites of services to customers through a reliable, one-stop, and hassle-free transaction experience. It derives revenues from retail vehicle sales, wholesale vehicle sales, and other businesses. The Group generates its revenues in China.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.